Acute, chronic and conditioned effects of intranasal oxytocin in the mu-opioid receptor knockout mouse model of autism: Social context matters.


Journal

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907

Informations de publication

Date de publication:
17 Jul 2024
Historique:
received: 14 03 2024
accepted: 24 06 2024
revised: 29 05 2024
medline: 18 7 2024
pubmed: 18 7 2024
entrez: 17 7 2024
Statut: aheadofprint

Résumé

Autism Spectrum Disorders (ASD) are neurodevelopmental disorders whose diagnosis relies on deficient social interaction and communication together with repetitive behaviours. Multiple studies have highlighted the potential of oxytocin (OT) to ameliorate behavioural abnormalities in animal models and subjects with ASD. Clinical trials, however, yielded disappointing results. Our study aimed at assessing the behavioural effects of different regimens of OT administration in the Oprm1 null mouse model of ASD. We assessed the effects of intranasal OT injected once at different doses (0.15, 0.3, and 0.6 IU) and time points (5, 15, and 30 min) following administration, or chronically, on ASD-related behaviours (social interaction and preference, stereotypies, anxiety, nociception) in Oprm1

Identifiants

pubmed: 39020142
doi: 10.1038/s41386-024-01915-1
pii: 10.1038/s41386-024-01915-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

APA. Diagnostic and statistical manual of mental disorders. 2013 5th ed. ed.: Washington, DC.
Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics. 2007;120:1183–215.
pubmed: 17967920 doi: 10.1542/peds.2007-2361
Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet. 2014;383:896–910.
pubmed: 24074734 doi: 10.1016/S0140-6736(13)61539-1
Ramaswami G, Geschwind DH. Genetics of autism spectrum disorder. Handb Clin Neurol. 2018;147:321–29.
pubmed: 29325621 doi: 10.1016/B978-0-444-63233-3.00021-X
Satterstrom FK, Kosmicki JA, Wang J, Breen MS, De Rubeis S, An JY, et al. Large-Scale exome sequencing study implicates both developmental and functional changes in the neurobiology of autism. Cell 2020;180:568–84.
pubmed: 31981491 pmcid: 7250485 doi: 10.1016/j.cell.2019.12.036
Dove D, Warren Z, McPheeters ML, Taylor JL, Sathe NA, Veenstra-VanderWeele J. Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics. 2012;130:717–26.
pubmed: 23008452 pmcid: 4074627 doi: 10.1542/peds.2012-0683
Ji N, Findling RL. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry. 2015;28:91–101.
pubmed: 25602248 doi: 10.1097/YCO.0000000000000132
Yu Z, Zhang P, Tao C, Lu L, Tang C. Efficacy of nonpharmacological interventions targeting social function in children and adults with autism spectrum disorder: A systematic review and meta-analysis. PLoS One. 2023;18:e0291720.
pubmed: 37725597 pmcid: 10508624 doi: 10.1371/journal.pone.0291720
Dolen G, Darvishzadeh A, Huang KW, Malenka RC. Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. Nature. 2013;501:179–84.
pubmed: 24025838 pmcid: 4091761 doi: 10.1038/nature12518
Hung LW, Neuner S, Polepalli JS, Beier KT, Wright M, Walsh JJ, et al. Gating of social reward by oxytocin in the ventral tegmental area. Science. 2017;357:1406–11.
pubmed: 28963257 pmcid: 6214365 doi: 10.1126/science.aan4994
Oettl LL, Ravi N, Schneider M, Scheller MF, Schneider P, Mitre M, et al. Oxytocin enhances social recognition by modulating cortical control of early olfactory processing. Neuron. 2016;90:609–21.
pubmed: 27112498 pmcid: 4860033 doi: 10.1016/j.neuron.2016.03.033
Lin YT, Hsieh TY, Tsai TC, Chen CC, Huang CC, Hsu KS. Conditional deletion of Hippocampal CA2/CA3a Oxytocin receptors impairs the persistence of long-term social recognition memory in mice. J Neurosci. 2018;38:1218–31.
pubmed: 29279308 pmcid: 6596267 doi: 10.1523/JNEUROSCI.1896-17.2017
Yoshihara C, Numan M, Kuroda KO. Oxytocin and parental behaviors. Curr Top Behav Neurosci. 2018;35:119–53.
pubmed: 28812267 doi: 10.1007/7854_2017_11
Walum H, Young LJ. The neural mechanisms and circuitry of the pair bond. Nat Rev Neurosci. 2018;19:643–54.
pubmed: 30301953 pmcid: 6283620 doi: 10.1038/s41583-018-0072-6
Ferretti V, Maltese F, Contarini G, Nigro M, Bonavia A, Huang H, et al. Oxytocin signaling in the central Amygdala modulates emotion discrimination in mice. Curr Biol: CB. 2019;29:1938–53. e6
pubmed: 31178317 doi: 10.1016/j.cub.2019.04.070
Caldwell HK, Aulino EA, Freeman AR, Miller TV, Witchey SK. Oxytocin and behavior: Lessons from knockout mice. Dev Neurobiol. 2017;77:190–201.
pubmed: 27513442 doi: 10.1002/dneu.22431
Sala M, Braida D, Lentini D, Busnelli M, Bulgheroni E, Capurro V, et al. Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry. 2011;69:875–82.
pubmed: 21306704 doi: 10.1016/j.biopsych.2010.12.022
Quintana DS, Lischke A, Grace S, Scheele D, Ma Y, Becker B. Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. Mol Psychiatry. 2021;26:80–91.
pubmed: 32807845 doi: 10.1038/s41380-020-00864-7
Tanaka A, Furubayashi T, Arai M, Inoue D, Kimura S, Kiriyama A, et al. Delivery of Oxytocin to the brain for the treatment of autism spectrum disorder by nasal application. Mol Pharm. 2018;15:1105–11.
pubmed: 29338251 doi: 10.1021/acs.molpharmaceut.7b00991
Hovey D, Martens L, Laeng B, Leknes S, Westberg L. The effect of intranasal oxytocin on visual processing and salience of human faces. Transl Psychiatry. 2020;10:318.
pubmed: 32951002 pmcid: 7502073 doi: 10.1038/s41398-020-00991-3
Shamay-Tsoory SG, Abu-Akel A. The social salience hypothesis of Oxytocin. Biol Psychiatry. 2016;79:194–202.
pubmed: 26321019 doi: 10.1016/j.biopsych.2015.07.020
Shahrestani S, Kemp AH, Guastella AJ. The impact of a single administration of intranasal oxytocin on the recognition of basic emotions in humans: a meta-analysis. Neuropsychopharmacology. 2013;38:1929–36.
pubmed: 23575742 pmcid: 3746698 doi: 10.1038/npp.2013.86
De Dreu CK, Greer LL, Handgraaf MJ, Shalvi S, Van Kleef GA, Baas M, et al. The neuropeptide oxytocin regulates parochial altruism in intergroup conflict among humans. Science. 2010;328:1408–11.
pubmed: 20538951 doi: 10.1126/science.1189047
Ma Y, Liu Y, Rand DG, Heatherton TF, Han S. Opposing Oxytocin effects on intergroup cooperative behavior in intuitive and reflective minds. Neuropsychopharmacology. 2015;40:2379–87.
pubmed: 25807529 pmcid: 4538352 doi: 10.1038/npp.2015.87
Hara Y, Ago Y, Higuchi M, Hasebe S, Nakazawa T, Hashimoto H, et al. Oxytocin attenuates deficits in social interaction but not recognition memory in a prenatal valproic acid-induced mouse model of autism. Horm Behav. 2017;96:130–36.
pubmed: 28942000 doi: 10.1016/j.yhbeh.2017.09.013
Meziane H, Schaller F, Bauer S, Villard C, Matarazzo V, Riet F, et al. An early postnatal Oxytocin treatment prevents social and learning deficits in adult mice deficient for Magel2, a gene involved in Prader-Willi Syndrome and autism. Biol Psychiatry. 2015;78:85–94.
pubmed: 25599930 doi: 10.1016/j.biopsych.2014.11.010
Bales KL, Solomon M, Jacob S, Crawley JN, Silverman JL, Larke RH, et al. Long-term exposure to intranasal oxytocin in a mouse autism model. Transl Psychiatry. 2014;4:e480.
pubmed: 25386957 pmcid: 4259989 doi: 10.1038/tp.2014.117
Cherepanov SM, Gerasimenko M, Yuhi T, Furuhara K, Tsuji C, Yokoyama S, et al. Oxytocin ameliorates impaired social behavior in a Chd8 haploinsufficiency mouse model of autism. BMC Neurosci. 2021;22:32.
pubmed: 33933000 pmcid: 8088024 doi: 10.1186/s12868-021-00631-6
Penagarikano O, Lazaro MT, Lu XH, Gordon A, Dong H, Lam HA, et al. Exogenous and evoked oxytocin restores social behavior in the Cntnap2 mouse model of autism. Sci Transl Med. 2015;7:271ra8.
pubmed: 25609168 pmcid: 4498455 doi: 10.1126/scitranslmed.3010257
Teng BL, Nikolova VD, Riddick NV, Agster KL, Crowley JJ, Baker LK, et al. Reversal of social deficits by subchronic oxytocin in two autism mouse models. Neuropharmacology. 2016;105:61–71.
pubmed: 26748053 doi: 10.1016/j.neuropharm.2015.12.025
Harony-Nicolas H, Kay M, du Hoffmann J, Klein ME, Bozdagi-Gunal O, Riad M, et al. Oxytocin improves behavioral and electrophysiological deficits in a novel Shank3-deficient rat. eLife. 2017;6:e18904.
pubmed: 28139198 pmcid: 5283828 doi: 10.7554/eLife.18904
Bertoni A, Schaller F, Tyzio R, Gaillard S, Santini F, Xolin M, et al. Oxytocin administration in neonates shapes hippocampal circuitry and restores social behavior in a mouse model of autism. Mol Psychiatry. 2021;26:7582–95.
pubmed: 34290367 pmcid: 8872977 doi: 10.1038/s41380-021-01227-6
Baker E, Stavropoulos KKM. The effects of oxytocin administration on individuals with ASD: Neuroimaging and behavioral evidence. Prog Mol Biol Transl Sci. 2020;173:209–38.
pubmed: 32711811 doi: 10.1016/bs.pmbts.2020.04.009
Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67:692–4.
pubmed: 19897177 doi: 10.1016/j.biopsych.2009.09.020
Sikich L, Kolevzon A, King BH, McDougle CJ, Sanders KB, Kim SJ, et al. Intranasal Oxytocin in children and adolescents with autism spectrum disorder. N. Engl J Med. 2021;385:1462–73.
pubmed: 34644471 pmcid: 9701092 doi: 10.1056/NEJMoa2103583
Yamasue H, Okada T, Munesue T, Kuroda M, Fujioka T, Uno Y, et al. Effect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trial. Mol Psychiatry. 2020;25:1849–58.
pubmed: 29955161 doi: 10.1038/s41380-018-0097-2
Feng C, Lori A, Waldman ID, Binder EB, Haroon E, Rilling JK. A common oxytocin receptor gene (OXTR) polymorphism modulates intranasal oxytocin effects on the neural response to social cooperation in humans. Genes Brain Behav. 2015;14:516–25.
pubmed: 26178189 doi: 10.1111/gbb.12234
Watanabe T, Otowa T, Abe O, Kuwabara H, Aoki Y, Natsubori T, et al. Oxytocin receptor gene variations predict neural and behavioral response to oxytocin in autism. Soc Cogn Affect Neurosci. 2017;12:496–506.
pubmed: 27798253 doi: 10.1093/scan/nsw150
Guastella AJ, Boulton KA, Whitehouse AJO, Song YJ, Thapa R, Gregory SG, et al. The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial. Mol Psychiatry. 2023;28:834–42.
pubmed: 36302965 doi: 10.1038/s41380-022-01845-8
Huang H, Michetti C, Busnelli M, Manago F, Sannino S, Scheggia D, et al. Chronic and acute intranasal oxytocin produce divergent social effects in mice. Neuropsychopharmacology. 2014;39:1102–14.
pubmed: 24190025 doi: 10.1038/npp.2013.310
de Jong TR, Neumann ID. Oxytocin and aggression. Curr Top Behav Neurosci. 2018;35:175–92.
pubmed: 28864975 doi: 10.1007/7854_2017_13
Anpilov S, Shemesh Y, Eren N, Harony-Nicolas H, Benjamin A, Dine J, et al. Wireless optogenetic stimulation of oxytocin neurons in a semi-natural setup dynamically elevates both pro-social and agonistic behaviors. Neuron. 2020;107:644–55. e7
pubmed: 32544386 pmcid: 7447984 doi: 10.1016/j.neuron.2020.05.028
Ford CL, Young LJ. Refining oxytocin therapy for autism: context is key. Nat Rev Neurol. 2022;18:67–68.
pubmed: 34880473 pmcid: 8816821 doi: 10.1038/s41582-021-00602-9
Yamasue H. Is the efficacy of oxytocin for autism diminished at higher dosages or repeated doses?: Potential mechanisms and candidate solutions. Peptides. 2024;171:171133.
pubmed: 38072084 doi: 10.1016/j.peptides.2023.171133
Becker JA, Clesse D, Spiegelhalter C, Schwab Y, Le Merrer J, Kieffer BL. Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity. Neuropsychopharmacology. 2014;39:2049–60.
pubmed: 24619243 pmcid: 4104328 doi: 10.1038/npp.2014.59
Derieux C, Leaute A, Brugoux A, Jaccaz D, Terrier C, Pin JP, et al. Chronic sodium bromide treatment relieves autistic-like behavioral deficits in three mouse models of autism. Neuropsychopharmacology. 2022;47:1680–92.
pubmed: 35418620 pmcid: 9283539 doi: 10.1038/s41386-022-01317-1
Moles A, Kieffer BL, D’Amato FR. Deficit in attachment behavior in mice lacking the mu-opioid receptor gene. Science. 2004;304:1983–6.
pubmed: 15218152 doi: 10.1126/science.1095943
Toddes C, Lefevre EM, Brandner DD, Zugschwert L, Rothwell PE. Mu Opioid Receptor (Oprm1) copy number influences nucleus accumbens microcircuitry and reciprocal social behaviors. J Neurosci. 2021;41:7965–77.
pubmed: 34301826 pmcid: 8460143 doi: 10.1523/JNEUROSCI.2440-20.2021
Pujol CN, Pellissier LP, Clement C, Becker JAJ, Le Merrer J. Back-translating behavioral intervention for autism spectrum disorders to mice with blunted reward restores social abilities. Transl Psychiatry. 2018;8:197.
pubmed: 30242222 pmcid: 6155047 doi: 10.1038/s41398-018-0247-y
Gigliucci V, Leonzino M, Busnelli M, Luchetti A, Palladino VS, D’Amato FR, et al. Region specific up-regulation of oxytocin receptors in the opioid oprm1 (-/-) mouse model of autism. Front Pediatr. 2014;2:91.
pubmed: 25225634 pmcid: 4150055 doi: 10.3389/fped.2014.00091
Frantz MC, Pellissier LP, Pflimlin E, Loison S, Gandia J, Marsol C, et al. LIT-001, the first nonpeptide Oxytocin receptor agonist that improves social interaction in a mouse model of autism. J Med Chem. 2018;61:8670–92.
pubmed: 30199637 doi: 10.1021/acs.jmedchem.8b00697
Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. BMJ Open Sci. 2020;4:e100115.
pubmed: 34095516 pmcid: 7610906
Lilley E, Stanford SC, Kendall DE, Alexander SPH, Cirino G, Docherty JR, et al. ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. Br J Pharm. 2020;177:3611–16.
doi: 10.1111/bph.15178
Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature. 1996;383:819–23.
pubmed: 8893006 doi: 10.1038/383819a0
Bales KL, Perkeybile AM, Conley OG, Lee MH, Guoynes CD, Downing GM, et al. Chronic intranasal oxytocin causes long-term impairments in partner preference formation in male prairie voles. Biol Psychiatry. 2013;74:180–8.
pubmed: 23079235 doi: 10.1016/j.biopsych.2012.08.025
Dadds MR, MacDonald E, Cauchi A, Williams K, Levy F, Brennan J. Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord. 2014;44:521–31.
pubmed: 23888359 doi: 10.1007/s10803-013-1899-3
Fonteneau M, Brugoux A, Jaccaz D, Donello JE, Banerjee P, Le Merrer J, et al. The NMDA receptor modulator zelquistinel durably relieves behavioral deficits in three mouse models of autism spectrum disorder. Neuropharmacology. 2024;248:109889.
pubmed: 38401792 doi: 10.1016/j.neuropharm.2024.109889
Le Merrer J, Detraux B, Gandia J, De Groote A, Fonteneau M, de Kerchove d’Exaerde A, et al. Balance between projecting neuronal populations of the nucleus accumbens controls social behavior in mice. Biol Psychiatry. 2024;95:123–35.
pubmed: 37207936 doi: 10.1016/j.biopsych.2023.05.008
Conti F, Sertic S, Reversi A, Chini B. Intracellular trafficking of the human oxytocin receptor: evidence of receptor recycling via a Rab4/Rab5 “short cycle”. Am J Physiol Endocrinol Metab. 2009;296:E532–42.
pubmed: 19126785 doi: 10.1152/ajpendo.90590.2008
Bolognani F, Del Valle Rubido M, Squassante L, Wandel C, Derks M, Murtagh L, et al. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. 2019;11:eaat7838.
pubmed: 31043521 doi: 10.1126/scitranslmed.aat7838
Hasan MT, Althammer F, Silva da Gouveia M, Goyon S, Eliava M, Lefevre A, et al. A fear memory engram and its plasticity in the hypothalamic Oxytocin system. Neuron. 2019;103:133–46. e8
pubmed: 31104950 doi: 10.1016/j.neuron.2019.04.029
Peters S, Slattery DA, Uschold-Schmidt N, Reber SO, Neumann ID. Dose-dependent effects of chronic central infusion of oxytocin on anxiety, oxytocin receptor binding and stress-related parameters in mice. Psychoneuroendocrinology. 2014;42:225–36.
pubmed: 24636519 doi: 10.1016/j.psyneuen.2014.01.021
Steinman MQ, Duque-Wilckens N, Trainor BC. Complementary neural circuits for divergent effects of Oxytocin: Social approach versus social anxiety. Biol Psychiatry. 2019;85:792–801.
pubmed: 30503164 doi: 10.1016/j.biopsych.2018.10.008
Smith AS, Korgan AC, Young WS. Oxytocin delivered nasally or intraperitoneally reaches the brain and plasma of normal and oxytocin knockout mice. Pharmacol Res. 2019;146:104324.
pubmed: 31238093 pmcid: 6679720 doi: 10.1016/j.phrs.2019.104324
Borie AM, Dromard Y, Guillon G, Olma A, Manning M, Muscatelli F, et al. Correction of vasopressin deficit in the lateral septum ameliorates social deficits of mouse autism model. J Clin Invest. 2021;131:e144450.
pubmed: 33232306 pmcid: 7810497 doi: 10.1172/JCI144450
Hendaus MA, Jomha FA, Alhammadi AH. Vasopressin in the amelioration of social functioning in autism spectrum disorder. J Clin Med. 2019;8:1061.
pubmed: 31331023 pmcid: 6678231 doi: 10.3390/jcm8071061
Williams AV, Duque-Wilckens N, Ramos-Maciel S, Campi KL, Bhela SK, Xu CK, et al. Social approach and social vigilance are differentially regulated by oxytocin receptors in the nucleus accumbens. Neuropsychopharmacology. 2020;45:1423–30.
pubmed: 32198453 pmcid: 7360746 doi: 10.1038/s41386-020-0657-4
Borie AM, Agezo S, Lunsford P, Boender AJ, Guo JD, Zhu H, et al. Social experience alters oxytocinergic modulation in the nucleus accumbens of female prairie voles. Curr Biol. 2022;32:1026–37. e4
pubmed: 35108521 pmcid: 8930613 doi: 10.1016/j.cub.2022.01.014
Leonzino M, Ponzoni L, Braida D, Gigliucci V, Busnelli M, Ceresini I, et al. Impaired approach to novelty and striatal alterations in the oxytocin receptor deficient mouse model of autism. Horm Behav. 2019;114:104543.
pubmed: 31220463 doi: 10.1016/j.yhbeh.2019.06.007
Menon R, Grund T, Zoicas I, Althammer F, Fiedler D, Biermeier V, et al. Oxytocin signaling in the lateral Septum prevents social fear during lactation. Curr Biol. 2018;28:1066–78. e6
pubmed: 29551417 doi: 10.1016/j.cub.2018.02.044
Dai YC, Zhang HF, Schon M, Bockers TM, Han SP, Han JS, et al. Neonatal Oxytocin treatment ameliorates autistic-like behaviors and oxytocin deficiency in Valproic acid-induced rat model of autism. Front Cell Neurosci. 2018;12:355.
pubmed: 30356897 pmcid: 6190900 doi: 10.3389/fncel.2018.00355
Szabo J, Mlynar M, Fejes A, Renczes E, Borbelyova V, Ostatnikova D, et al. Intranasal oxytocin in a genetic animal model of autism. Mol Psychiatry. 2023;29:342–7.
pubmed: 38102481 pmcid: 11116098 doi: 10.1038/s41380-023-02330-6
Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S, et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism. 2012;3:16.
pubmed: 23216716 pmcid: 3539865 doi: 10.1186/2040-2392-3-16
Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR, et al. Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger’s disorders. Neuropsychopharmacology. 2003;28:193–8.
pubmed: 12496956 doi: 10.1038/sj.npp.1300021
Drago F, Pedersen CA, Caldwell JD, Prange AJ Jr. Oxytocin potently enhances novelty-induced grooming behavior in the rat. Brain Res. 1986;368:287–95.
pubmed: 3697728 doi: 10.1016/0006-8993(86)90573-1
Marroni SS, Nakano FN, Gati CD, Oliveira JA, Antunes-Rodrigues J, Garcia-Cairasco N. Neuroanatomical and cellular substrates of hypergrooming induced by microinjection of oxytocin in central nucleus of amygdala, an experimental model of compulsive behavior. Mol Psychiatry. 2007;12:1103–17.
pubmed: 17505467 doi: 10.1038/sj.mp.4002015
Neumann ID, Slattery DA. Oxytocin in general anxiety and social fear: a translational approach. Biol Psychiatry. 2016;79:213–21.
pubmed: 26208744 doi: 10.1016/j.biopsych.2015.06.004
Iwasaki M, Lefevre A, Althammer F, Clauss Creusot E, Lapies O, Petitjean H, et al. An analgesic pathway from parvocellular oxytocin neurons to the periaqueductal gray in rats. Nat Commun. 2023;14:1066.
pubmed: 36828816 pmcid: 9958129 doi: 10.1038/s41467-023-36641-7
Nersesyan Y, Demirkhanyan L, Cabezas-Bratesco D, Oakes V, Kusuda R, Dawson T, et al. Oxytocin modulates Nociception as an agonist of pain-sensing TRPV1. Cell Rep. 2017;21:1681–91.
pubmed: 29117570 pmcid: 5701661 doi: 10.1016/j.celrep.2017.10.063
Borie AM, Young LJ, Liu RC. Sex-specific and social experience-dependent oxytocin-endocannabinoid interactions in the nucleus accumbens: implications for social behaviour. Philos Trans R Soc Lond B Biol Sci. 2022;377:20210057.
pubmed: 35858094 pmcid: 9272148 doi: 10.1098/rstb.2021.0057
Borroto-Escuela DO, Cuesta-Marti C, Lopez-Salas A, Chruscicka-Smaga B, Crespo-Ramirez M, Tesoro-Cruz E, et al. The oxytocin receptor represents a key hub in the GPCR heteroreceptor network: potential relevance for brain and behavior. Front Mol Neurosci. 2022;15:1055344.
pubmed: 36618821 pmcid: 9812438 doi: 10.3389/fnmol.2022.1055344
Svenningsson P, Le Moine C, Kull B, Sunahara R, Bloch B, Fredholm BB. Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience. 1997;80:1171–85.
pubmed: 9284069 doi: 10.1016/S0306-4522(97)00180-2
Ferre S, von Euler G, Johansson B, Fredholm BB, Fuxe K. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA. 1991;88:7238–41.
pubmed: 1678519 pmcid: 52269 doi: 10.1073/pnas.88.16.7238
Georgiou P, Zanos P, Garcia-Carmona JA, Hourani S, Kitchen I, Kieffer BL, et al. The oxytocin analogue carbetocin prevents priming-induced reinstatement of morphine-seeking: Involvement of dopaminergic, noradrenergic and MOPr systems. Eur Neuropsychopharmacol. 2015;25:2459–64.
pubmed: 26475574 doi: 10.1016/j.euroneuro.2015.09.015
Le J, Zhang L, Zhao W, Zhu S, Lan C, Kou J, et al. Infrequent intranasal Oxytocin followed by positive social interaction improves symptoms in autistic children: a pilot randomized clinical trial. Psychother Psychosom. 2022;91:335–47.
pubmed: 35545057 doi: 10.1159/000524543
Stavropoulos KK, Carver LJ. Research review: Social motivation and oxytocin in autism–implications for joint attention development and intervention. J Child Psychol Psychiatry. 2013;54:603–18.
pubmed: 23451765 pmcid: 3663901 doi: 10.1111/jcpp.12061
Ventola P, Yang DY, Friedman HE, Oosting D, Wolf J, Sukhodolsky DG, et al. Heterogeneity of neural mechanisms of response to pivotal response treatment. Brain Imaging Behav. 2015;9:74–88.
pubmed: 25370452 pmcid: 4993028 doi: 10.1007/s11682-014-9331-y

Auteurs

Fani Pantouli (F)

INRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France.
Florida Research & Innovation Center, Cleveland Clinic, 9801 SW Discovery Way, Port St. Lucie, FL, 34987, USA.
Pharmacology section, Institute of Medical and Biomedical Education, St George's University of London, London, SW17 ORE, UK.

Camille N Pujol (CN)

INRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France.
Department of Psychiatry, Strasbourg University Hospital, 67091, Strasbourg, France.

Cécile Derieux (C)

INRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France.

Mathieu Fonteneau (M)

UMR1253, iBrain, Université de Tours, Inserm, CNRS, Faculté des Sciences et Techniques, Parc de Grandmont, 37200, Tours, France.

Lucie P Pellissier (LP)

INRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France.

Claire Marsol (C)

Laboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 route du Rhin, 67412, Illkirch, France.

Julie Karpenko (J)

Laboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 route du Rhin, 67412, Illkirch, France.

Dominique Bonnet (D)

Laboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 route du Rhin, 67412, Illkirch, France.

Marcel Hibert (M)

Laboratoire d'Innovation Thérapeutique, Faculté de Pharmacie, UMR7200 CNRS/Université de Strasbourg, 74 route du Rhin, 67412, Illkirch, France.

Alexis Bailey (A)

Pharmacology section, Institute of Medical and Biomedical Education, St George's University of London, London, SW17 ORE, UK.

Julie Le Merrer (J)

INRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France. Julie.le-merrer@inserm.fr.
UMR1253, iBrain, Université de Tours, Inserm, CNRS, Faculté des Sciences et Techniques, Parc de Grandmont, 37200, Tours, France. Julie.le-merrer@inserm.fr.

Jerome A J Becker (JAJ)

INRAE, CNRS, Université de Tours, Inserm, PRC, 37380, Nouzilly, France. Jerome.becker@inserm.fr.
UMR1253, iBrain, Université de Tours, Inserm, CNRS, Faculté des Sciences et Techniques, Parc de Grandmont, 37200, Tours, France. Jerome.becker@inserm.fr.

Classifications MeSH